Blockade of the V1b receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity

Journal of Endocrinology

Volumn 200, Issue 3, 2009, Pages 273-283

  Spiga, Francesca ^a   Harrison, Louise R ^a   Wood, Susan ^a   Knight, David M ^a   MacSweeney, Cliona P ^b   Thomson, Fiona ^b   Craighead, Mark ^b   Lightman, Stafford L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; LIPOPOLYSACCHARIDE; VASOPRESSIN; VASOPRESSIN V1B RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CENTRIFUGATION; CIRCADIAN RHYTHM; CONTROLLED STUDY; CORTICOSTERONE RELEASE; CORTICOTROPIN RELEASE; HORMONE RESPONSE; HORMONE SYNTHESIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; STRESS; ULTRADIAN RHYTHM;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; CORTICOSTERONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; NOISE; PITUITARY-ADRENAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; RESTRAINT, PHYSICAL; STRESS, PHYSIOLOGICAL;

EID: 67449123561     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-08-0421     Document Type: Article

References (56)

1. Aguilera G 1994 Regulation of pituitary ACTH secretion during chronic stress. Frontiers in Neuroendocrinology 15 321-350.
2. Aguilera G & Rabadan-Diehl C 2000 Regulation of vasopressin V1b receptors in the anterior pituitary gland of the rat. Experimental Physiology 85 19S-26S.
3. Aguilera G, Pham Q & Rabadan-Diehl C 1994 Regulation of pituitary vasopressin receptors during chronic stress: relationship to corticotroph responsiveness. Journal of Neuroendocrinology 6 299-304.
4. Antoni FA 1993 Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Frontiers in Neuroendocrinology 14 76-122.
5. Breuer MF, van Gaalen MM, Wernet W, Claessens SE, Oosting RS, Behl B, Korte SM, Schoemaker H, Gross G, Olivier B et al. 2008 SSR149415, a non-peptide vasopressin V(1b) receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model. Naunyn Schmiedeberg's Archives of Pharmacology DOI: 10.1007/S00210-008-0336-1 (in press)
6. Carnes M, Lent S, Feyzi J & Hazel D 1989 Plasma adrenocorticotropic hormone in the rat demonstrates three different rhythms within 24 h. Neuroendocrinology 50 17-25.
7. Chowdrey HS, Larsen PJ, Harbuz MS, Jessop DS, Aguilera G, Eckland DJ & Lightman SL 1995 Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. British Journal of Pharmacology 116 2417-2424.
8. Craighead M, Milne R, Campbell-Wan L,Watson L, Presland J, Thomson FJ, Marston HM & Macsweeney CP 2008 Characterization of a novel and selective V(1B) receptor antagonist. Progress in Brain Research 170 527-535.
9. Dallman MF, Engeland WC, Rose JC, Wilkinson CW, Shinsako J & Siedenburg F 1978 Nycthemeral rhythm in adrenal responsiveness to ACTH. American Journal of Physiology 235 R210-R218.
10. Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S & Grossman AB 1999 Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. Journal of Clinical Endocrinology and Metabolism 84 2238-2240.
11. Dinan TG, O'Brien S, Lavelle E & Scott LV 2004 Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychological Medicine 34 169-172.
12. Engeland WC & Arnhold MM 2005 Neural circuitry in the regulation of adrenal corticosterone rhythmicity. Endocrine 28 325-332.
13. Gillies GE, Linton EA & Lowry PJ 1982 Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299 355-357.
14. de Goeij DC, Kvetnansky R, Whitnall MH, Jezova D, Berkenbosch F & Tilders FJ 1991 Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats. Neuroendocrinology 53 150-159.
15. de Goeij DC, Jezova D & Tilders FJ 1992 Repeated stress enhances vasopressin synthesis in corticotropin releasing factor neurons in the paraventricular nucleus. Brain Research 577 165-168.
16. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP & Soubrie P 2002 Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. PNAS 99 6370-6375.
17. Henley DE, Russell GM, Wood SA, Leendertz JA, Woltersdorf WW, Catterall JR & Lightman SL 2008 HPA axis activation in obstructive sleep apnea - preliminary findings. Abstract of the Endocrine Society's Annual Meeting, June 15-18, 2008, San Francisco, CA, USA.
18. Holsboer F 2000 The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 477-501.
19. Holsboer F 2001 Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. Journal of Affective Disorders 62 77-91.
20. Iijima M & Chaki S 2007 An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31 622-627.
21. Jard S, Barberis C, Audigier S & Tribollet E 1987 Neurohypophyseal hormone receptor systems in brain and periphery. Progress in Brain Research 72 173-187.
22. Jasper MS & Engeland WC 1991 Synchronous ultradian rhythms in adrenocortical secretion detected by microdialysis in awake rats. American Journal of Physiology 261 R1257-R1268.
23. Jochum T, Boettger MK, Wigger A, Beiderbeck D, Neumann ID, Landgraf R, Sauer H & Bar KJ 2007 Decreased sensitivity to thermal pain in rats bred for high anxiety-related behaviour is attenuated by citalopram or diazepam treatment. Behavioral Brain Research 183 18-24.
24. Kaneko M, Hiroshige T, Shinsako J & Dallman MF 1980 Diurnal changes in amplification of hormone rhythms in the adrenocortical system. American Journal of Physiology 239 R309-R316.
25. Kaneko M, Kaneko K, Shinsako J & Dallman MF 1981 Adrenal sensitivity to adrenocorticotropin varies diurnally. Endocrinology 109 70-75.
26. Keck ME, Wigger A, Welt T, Muller MB, Gesing A, Reul JM, Holsboer F, Landgraf R & Neumann ID 2002 Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 26 94-105.
27. de Kloet CS, Vermetten E, Geuze E, Wiegant VM & Westenberg HG 2007 Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder. Journal of Psychiatric Research.
28. Lolait SJ, O'Carroll AM, Mahan LC, Felder CC, Button DC, Young WS III, Mezey E & Brownstein MJ 1995 Extrapituitary expression of the rat V1b vasopressin receptor gene. PNAS 92 6783-6787.
29. Lolait SJ, Stewart LQ, Jessop DS, Young WS III & O'Carroll AM 2007a The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 148 849-856.
30. Lolait SJ, Stewart LQ, Roper JA, Harrison G, Jessop DS, Young WS III & O'Carroll AM 2007b Attenuated stress response to acute lipopolysaccharide challenge and ethanol administration in vasopressin V1b receptor knockout mice. Journal of Neuroendocrinology 19 543-551.
31. van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA & De Wied D 1997 Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17 284-292.
32. van Londen L, Kerkhof GA, van den BF, Goekoop JG, Zwinderman KH, Frankhuijzen-Sierevogel AC, Wiegant VM & De WD 1998 Plasma arginine vasopressin and motor activity in major depression. Biological Psychiatry 43 196-204.
33. van Londen L, Goekoop JG, Kerkhof GA, Zwinderman KH, Wiegant VM & De WD 2001 Weak 24-h periodicity of body temperature and increased plasma vasopressin in melancholic depression. European Neuropsychopharmacology 11 7-14.
34. Ma XM & Lightman SL 1998 The arginine vasopressin and corticotrophinreleasing hormone gene transcription responses to varied frequencies of repeated stress in rats. Journal of Physiology 510 605-614.
35. Ma XM, Levy A & Lightman SL 1997a Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. Endocrinology 138 4351-4357.
36. Ma XM, Levy A & Lightman SL 1997b Rapid changes of heteronuclear RNA for arginine vasopressin but not for corticotropin releasing hormone in response to acute corticosterone administration. Journal of Neuroendocrinology 9 723-728.
37. Makino S, Smith MA & Gold PW 1995 Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: association with reduction in glucocorticoid receptor mRNA levels. Endocrinology 136 3299-3309.
38. Merali Z, Kent P, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Bedard T & Anisman H 2006 Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biological Psychiatry 59 594-602.
39. Merriam GR & Wachter KW 1982 Algorithms for the study of episodic hormone secretion. American Journal of Physiology 243 E310-E318.
40. Michael RP & Gibbson JL 1963 Interrelationships bethween the endocrine system and neuropsychiatry. International Review of Neurobiology 5 243-302.
41. Mlynarik M, Zelena D, Bagdy G, Makara GB & Jezova D 2007 Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Hormones and Behavior 51 395-405.
42. Presland J, Thomson F, Milne R, MacSweeney C, Campbell-Wan L, Watson M & Craighead M 2007 In vitro and in vivo characterisation of a novel antagonist for the type 1B vasopressin receptor (V1B (V3)). Abstract of the 37th Annual Meeting of the Society for Neuroscience, 4-7 November 2007, San Diego, CA, USA.
43. Purba JS, Hoogendijk WJ, Hofman MA & Swaab DF 1996 Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Archives of General Psychiatry 53 137-143.
44. Rabadan-Diehl C, Lolait SJ & Aguilera G 1995 Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat. Journal of Neuroendocrinology 7 903-910.
45. Ramos AT, Troncone LR & Tufik S 2006 Suppression of adrenocorticotrophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stress models. Neuroendocrinology 84 309-316.
46. Rivier C, Rivier J, Mormede P & Vale W 1984 Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat. Endocrinology 115 882-886.
47. Serradeil-Le Gal C,Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrie P, Nisato D et al. 2002 Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl) sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl] -4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 300 1122-1130.
48. Serradeil-Le Gal C,Wagnon J III, Tonnerre B, Roux R, Garcia G, Griebel G & Aulombard A 2005 An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Reviews 11 53-68.
49. Shimazaki T, Iijima M & Chaki S 2006 The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats. European Journal of Pharmacology 543 63-67.
50. Spiga F, Harrison LR,Wood SA, Atkinson HC,Macsweeney CP, Thomson F, Craighead M, Grassie M & Lightman SL 2007 Effect of the glucocorticoid receptor antagonist Org 34850 on basal and stress-induced corticosterone secretion. Journal of Neuroendocrinology 19 891-900.
51. Stewart LQ, Roper JA, Young WS III, O'Carroll AM & Lolait SJ 2008 Pituitary-adrenal response to acute and repeated mild restraint, forced swim and change in environment stress in arginine vasopressin receptor 1b knockout mice. Journal of Neuroendocrinology 20 597-605.
52. Vaccari C, Lolait SJ & Ostrowski NL 1998 Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology 139 5015-5033
53. van West D, Del-Favero J, Aulchenko Y, Oswald P, Souery D, Forsgren T, Sluijs S, Bel-Kacem S, Adolfsson R, Mendlewicz J et al. 2004 A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Molecular Psychiatry 9 287-292.
54. Windle RJ, Wood SA, Lightman SL & Ingram CD 1998 The pulsatile characteristics of hypothalamo-pituitary-adrenal activity in female Lewis and Fischer 344 rats and its relationship to differential stress responses. Endocrinology 139 4044-4052.
55. de Winter RF, van Hemert AM, Derijk RH, Zwinderman KH, Frankhuijzen-Sierevogel AC, Wiegant VM & Goekoop JG 2003 Anxiousretarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 28 140-147.
56. Zelena D, Mergl Z & Makara GB 2006 The role of vasopressin in diabetes mellitus-induced hypothalamo-pituitary-adrenal axis activation: studies in Brattleboro rats. Brain Research Bulletin 69 48-56.